Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Deepika Sharma Das, PhD, Vincent Macri, MA, Janice Chen, PhD, Claudia Paba-Praba, Paul G. Richardson, MD, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4463.

https://doi.org/10.1182/blood.V128.22.4463.4463

Published: 2016

Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

John Gionco, Janice Chen, PhD, Ross Lindsay, PhD, Vince Macri, M.A., Christopher L. Brooks, PhD

Blood (2016) 128 (22): 4724.

https://doi.org/10.1182/blood.V128.22.4724.4724

Published: 2016

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey Zonder, MD, Thomas G. Martin, III, MD, Emma C. Scott, MD, Janice Chen, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Claudia E. Paba-Prada, MD

Blood (2016) 128 (22): 5696.

https://doi.org/10.1182/blood.V128.22.5696.5696

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Blood (2016) 128 (22): 215.

https://doi.org/10.1182/blood.V128.22.215.215

Published: 2016

Journal Articles

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Janice Chen, PhD, Shay Shemesh, MA, Peter McDonald, Christopher L. Brooks, PhD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 342.

https://doi.org/10.1182/blood.V128.22.342.342

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Blood (2016) 128 (22): 4245.

https://doi.org/10.1182/blood.V128.22.4245.4245

Published: 2016

Journal Articles

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Kendra L. Sweet, MD, Naveen Pemmaraju, MD, Andrew A Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Eric K. Rowinsky, MD, Michael Szarek, PhD, Christopher L. Brooks, PhD, Sarah Disalvatore, MPH, David Liu, Madeleine Duvic, MD, Jonathan D. Schwartz, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3795.

https://doi.org/10.1182/blood.V126.23.3795.3795

Published: 2015

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Amanda L Christie, B.S., Yvonne Li, PhD, Katsuhiro Togami, MD, Mahmoud Ghandi, PhD, Alexandra N. Christodoulou, M.S., Kevin Buczkowski, Fanny Angelot-Delettre, PhD, Sabeha Biichle, Janice Chen, PhD, Christopher L. Brooks, PhD, David M. Weinstock, MD, Francine Garnache-Ottou, PhD, Peter S Hammerman, MD PhD, Andrew A Lane, MD PhD

Blood (2015) 126 (23): 3797.

https://doi.org/10.1182/blood.V126.23.3797.3797

Published: 2015

Journal Articles

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Janice Chen, PhD, Christopher L. Brooks, PhD, Peter McDonald, Jonathan D. Schwartz, MD, Rebecca S. Schneider, Keiichi Sakakibara, PhD, Naoya Saito, PhD, Takuji Sato, MSc, Takumi Kawabe, MD PhD, Eric K. Rowinsky, MD

Blood (2015) 126 (23): 4433.

https://doi.org/10.1182/blood.V126.23.4433.4433

Published: 2015

Journal Articles

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

Arghya Ray, PhD, Deepika Sharma DAS, PhD, Yan Song, PhD, Vincent Macri, MA, Christopher L. Brooks, PhD, Eric K. Rowinsky, MD, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 3000.

https://doi.org/10.1182/blood.V126.23.3000.3000

Published: 2015

Journal Articles

CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value

Animesh Pardanani, MBBS, PhD, Kaaren Reichard, MD, Darci Zblewski, CNP, Ramy Abdelrahman, M.B.,B.Ch., Emnet Wassie, MD, William G. Morice, MD PhD, Christopher L. Brooks, PhD, Curtis A. Hanson, MD, Ayalew Tefferi, MD, Dong Chen, MD PhD

Blood (2015) 126 (23): 2802.

https://doi.org/10.1182/blood.V126.23.2802.2802

Published: 2015

Journal Articles

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Delettre Fanny, PhD, Arthur E. Frankel, MD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Eric Deconninck, MD, Francis Bonnefoy, PhD, Baptiste Lamarthee, PhD Student, Christopher L. Brooks, PhD, Eric Rowinsky, MD, Philippe Saas, Ph.D., Francine Garnache Ottou, PhD

Blood (2013) 122 (21): 3942.

https://doi.org/10.1182/blood.V122.21.3942.3942

Published: 2013

Journal Articles

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

Arghya Ray, Ph.D, Deepika Sharma Das, Ph.D., Ze Tian, Ph.D, Vincent Macri, Christopher L. Brooks, PhD, Paul G. Richardson, MD, Eric Rowinsky, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3170.

https://doi.org/10.1182/blood.V122.21.3170.3170

Published: 2013

Journal Articles

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

Christopher L. Brooks, PhD, Thomas P. Cirrito, PhD, Kenneth Hoberman, Eric Rowinsky, MD

Blood (2012) 120 (21): 2768.

https://doi.org/10.1182/blood.V120.21.2768.2768

Published: 2012

Journal Articles

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Fanny Angelot-Delettre, PhD, Arthur E. Frankel, MD, Jen Sing Liu, PhD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Bernard Drenou, MD, PhD, Mark L. Jacobson, MA, Thomas P. Cirrito, PhD, Arkam Yazid, MD, Eric Deconinck, MD, PhD, Christopher L. Brooks, PhD, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2011) 118 (21): 2588.

https://doi.org/10.1182/blood.V118.21.2588.2588

Published: 2011

Journal Articles

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Christopher L. Brooks, PhD, Jairo Baquero-Buitrago, MSc, Crystal Cruz, Isabelita Vengco, Francesca Montanari, MD, Enrica Marchi, MD, Ph.D., Luigi Scotto, Ph.D., Thomas P. Cirrito, PhD, Ivan Bergstein, MD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3737.

https://doi.org/10.1182/blood.V118.21.3737.3737

Published: 2011

NARROW

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only